Sample Solution

Research Centre, Tumkur, during the period of November 2016 to April 2018.
INCLUSION CRITERIA: Women of reproductive age group diagnosed with dysfunctional uterine bleeding.
EXCLUSION CRITERIA: Patient with pelvic pathology-uterine fibroid, PID, adenomyosis, endometriosis, chronic cervicitis and malignancies of uterus / cervix /ovary / vagina / complex endometrial hyperplasia with atypia and platelet disorders, coagulopathy, previous history of thrombosis,Pregnancy and lactation, PCOS, Hypothyroidism, Chronic cervicitis, Jaundice, hepatic dysfunction, Tb, renal impairment, Hypersensitivity to drug were excluded.
An informed written consent from all the women who were included in the study were taken. A detailed history, complete physical examination, routine investigations like hemoglobin, bleeding time, clotting time, platelet, RBS, thyroid function tests, liver function test, transvaginal USG to rule out pelvic pathology and to measure endometrial thickness were done to all patients.
The recruitment of the participants to the study groups were done after explaining about the merits and demerits of Ormeloxifene and LNG-IUCD.
As by their choices, the subjects were allocated into 2 groups. Group ormeloxifene and Group levonorgestrel IUCD.
For group ormeloxifene , the drug ormeloxifene was administered orally in the form of tablet (60mg) twice a week, for first 12 weeks and then once a week for another 12 weeks and for other LEVONORGESTEROL intra uterine contraceptive device was inserted. They were advised to attend four weekly or earlier if required to OPD for follow up.